MiNK Therapeutics, Inc. — Director's Dealing 2021

Oct 21, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: MiNK Therapeutics, Inc. (INKT)
CIK: 0001840229
Period of Report: 2021-10-13

Reporting Person: ARMEN GARO H (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2226400	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$0.02	2028-11-19	Common Stock (27830)		Direct
Stock Option (Right to Buy)	$0.02	2028-11-19	Common Stock (27830)		Direct
Stock Option (Right to Buy)	$0.01	2030-01-30	Common Stock (695750)		Direct
Stock Option (Right to Buy)	$3.03	2021-02-11	Common Stock (834900)		Direct

Footnotes

F1: Represents an option to purchase shares of the common stock, which vests as to 30% of the underlying shares on November 19, 2021 and as to the remaining 70% of the underlying shares on November 19, 2022, in each case, generally subject to continued employment.

F2: Represents an option to purchase shares of the common stock, which vests on or about December 31, 2022, as to a portion of the underlying shares as determined by the achievement of certain milestones between January 1, 2019 and December 31, 2022, with 20% vesting upon achievement of five milestones, and an additional 5% vesting for each.

F3: Represents an option to purchase shares of the common stock, which vested as to 33% of the underlying shares on January 30, 2021, and with respect to the remainder, in eight equal quarterly installments thereafter, in each case, generally subject to continued employment.

F4: Represents an option to purchase shares of the common stock, which vests as to 33% of the underlying shares on February 11, 2022, and with respect to the remainder, in eight equal quarterly installments thereafter, in each case, generally subject to continued employment.